IQVIA Introduces RIM Smart
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (NYSE:IQV) announced the launch of IQVIA RIM Smart, the first fully integrated, cloud-based, end-to-end regulatory information management solution for life sciences. Designed to leverage artificial intelligence (AI) and machine learning (ML), IQVIA Technologies’ new solution enables intelligent management of a product portfolio’s complete regulatory lifecycle.
“Life sciences companies are challenged by an increasingly complex, rapidly changing global regulatory environment within challenging financial constraints,” said Tal Rosenberg, senior vice president, Global Technology Solutions for IQVIA. “IQVIA RIM Smart is a technology-led solution for increasing speed, collaboration between functions, efficiency, and visibility across the full product portfolio, while also improving compliance performance.”
RIM Smart automates high-volume tasks, efficiently boosting accuracy, improving data quality, and reducing costs. This unique solution incorporates up-to-date regulatory intelligence information through the software, providing specific and detailed country-level regulatory requirements. Using an array of fully integrated modules that can be customized to meet specific customer needs, RIM Smart is appropriate for companies of all sizes.
“Built for regulatory professionals by regulatory professionals, RIM Smart will seamlessly integrate with IQVIA Technologies’ safety and quality compliance solutions. A range of open integration options gives customers the flexibility to plug and play, leveraging existing IT investments,” said Joe Rymsza, vice president, Pharmacovigilance and Regulatory Technology Solutions at IQVIA. “Delivered securely in the cloud and using proprietary AI and ML algorithms, IQVIA RIM Smart will provide interconnected, comprehensive and intelligent management of the entire regulatory process.”
More than a regulatory information management system, RIM Smart will provide content management, registration tracking, monitoring of health authority interactions and commitments, submission planning, publishing, and soon, product labeling and translation capabilities. It easily handles routine workflows, enabling clients to use their resources to focus on bringing safe and effective products to market and ultimately driving healthcare forward. For more information visit http://iqvia.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science - leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science - to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 58,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
